References
- Thangavelu M, Olopade O, Beckman E, Vardiman J W, Larson R A, McKeithan T W, et al. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer 1990; 2: 1147–1158
- Tsimberidou A M, O'Brien S, Kantarjian H M, Koller C, Hagemeister F B, Fayad L, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M.D. Anderson Cancer Center experience. J Clin Oncol 2007; 25: 4648–4656
- Camacho F I, Garcia J F, Cigudosa J C, Mollejo M, Algara P, Ruiz-Ballesteros E, et al. Aberrant BCL6 protein expression in mantle cell lymphoma. Am J Surg Pathol 2004; 28: 1051–1056
- Nayer H, Murphy K M, Hawkins A L, Long P P, Gillison M, Borowitz M, et al. Clonal cytogenetic abnormalities and BCL2 rearrangements in interdigitating dendritic cell sarcoma. Leuk Lymphoma 2006; 47: 2447–2448
- Reddy K, Ansarui–Lari M, Dipasquale B. Blastic mantle cell lymphoma with a Burkitt translocation. Leuk Lymphoma 2008;49:740 – 750
- Michaux L, Wlodarska I, Theate I, Stul M, Scheiff J-M, Deneys V, et al. Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome. Ann Hematol 2004; 83: 578–583
- Rosenwald A, Wright G, Wiestner A, Chan W C, Conors J M, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197